Myasthenia gravis occurs when antibodies attack the nicotinic acetylcholine receptors at the neuromuscular junction leading to muscle weakness.

Choice A rationale Metabotropic receptors, such as G-protein coupled receptors, produce slower, more prolonged responses than ionotropic receptors like nicotinic receptors. Myasthenia gravis specifically targets the nicotinic acetylcholine receptors at the neuromuscular junction. The resulting insufficient signal transmission leads to muscle weakness, not muscle weakness mediated by a metabotropic receptor, making this choice incorrect. Choice B rationale Myasthenia gravis is an autoimmune disorder where antibodies target and destroy or block the nicotinic acetylcholine receptors on the postsynaptic membrane of the neuromuscular junction. This reduces the number of available receptor sites for acetylcholine, preventing adequate muscle depolarization and leading directly to impaired nerve-to-muscle signal transmission and resulting in characteristic muscle weakness and fatigue. Choice C rationale Dopaminergic receptors primarily mediate effects in the central nervous system, and adrenergic receptors mediate the effects of norepinephrine and epinephrine on the sympathetic nervous system. Neither of these receptor types is the target of the autoantibodies in myasthenia gravis, which specifically attack the nicotinic acetylcholine receptors, nor is the outcome muscle contraction. Choice D rationale Nicotinic receptors are the correct receptor class involved, but adrenergic is incorrect; the targeted receptors are nicotinic acetylcholine receptors. Furthermore, the reduction in available receptors leads to impaired signal transmission and the clinical manifestation of muscle weakness, not enhanced muscle contraction, which is contrary to the pathology of myasthenia gravis.